Cullinan Oncology Inc. (CGEM): Price and Financial Metrics

Cullinan Oncology Inc. (CGEM): $15.78

0.23 (+1.48%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

D

Add CGEM to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#274 of 328

in industry

CGEM Price/Volume Stats

Current price $15.78 52-week high $30.19
Prev. close $15.55 52-week low $7.64
Day low $15.45 Volume 463,500
Day high $15.90 Avg. volume 655,656
50-day MA $17.08 Dividend yield N/A
200-day MA $18.41 Market Cap 914.88M

CGEM Stock Price Chart Interactive Chart >


Cullinan Oncology Inc. (CGEM) Company Bio


Cullinan Management, Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Management, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.


CGEM Latest News Stream


Event/Time News Detail
Loading, please wait...

CGEM Latest Social Stream


Loading social stream, please wait...

View Full CGEM Social Stream

CGEM Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year N/A
5-year N/A
YTD N/A
2023 N/A
2022 N/A
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!